Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by M.Yu. Frolov
Pharmacoeconomic Study of Pembrolizumab and Nivolumab in the Second Line of Therapy of Advanced Non-Small Cell Lung Cancer
Effective Pharmacotherapy
Related publications
P1.04-29 Second or Third Line Nivolumab Versus First Line Nivolumab in Patients With Previously Treated Advanced Non Small Cell Lung Cancer (NSCLC)
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Phase II Study of Vinorelbine and Docetaxel in the Treatment of Advanced Non–Small-Cell Lung Cancer as Frontline and Second-Line Therapy
American Journal of Clinical Oncology: Cancer Clinical Trials
Cancer Research
Oncology
Pharmacoeconomic Evaluation of PD-L1 Receptor Inhibitors for the Second Line Treatment of Metastatic Non-Small Cell Lung Cancer
Medical Technologies. Assessment and Choice
Cost-Effectiveness of First-Line Therapy for Advanced Non-Small Cell Lung Cancer (Nsclc)
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pcn4 - Effectiveness and Safety of Pembrolizumab in Advanced or Metastatic Non-Small Cell Lung Cancer
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Nivolumab in Metastatic Non–Small Cell Lung Cancer
Journal of the Advanced Practitioner in Oncology
Anaplastic Lymphoma Kinase (ALK) Inhibitors for Second-Line Therapy of Non-Small Cell Lung Cancer
Lung Cancer: Targets and Therapy
Oncology
Predictive Role of Plasmatic Biomarkers in Advanced Non-Small Cell Lung Cancer Treated by Nivolumab
OncoImmunology
Oncology
Allergy
Immunology
Words (Excluding Tãtle and Authors: 300) Title: Cost-Effectiveness Analysis of Nivolumab for the Treatment of Second-Line Advanced Squamous Non-Small Cell Lung Cancer (Nsclc) in Spain
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
